| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
|
Medicine details |
|
| Medicine name | etanercept (Enbrel®) |
| Formulation | powder and solvent for solution for injection |
| Reference number | 137 |
| Indication | Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy |
| Company | Pfizer Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/02/2006 |
| NICE guidance | TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |